▶ ORFORGLIPRON · SUBTOPIC · MECHANISM
ORFORGLIPRON Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Eli Lilly oral non-peptide small-molecule GLP-1 receptor agonist (LY3502970). First oral GLP-1 designed for once-daily tablet dosing, bypassing the injection requirement of peptide GLP-1s. ACHIEVE-1 Phase 3 readout expected 2026.
PHARMACOKINETIC HALF-LIFE
Reported half-life for ORFORGLIPRON: ~24-30 hours (once-daily oral). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
ORFORGLIPRON is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (GH-axis reference). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Wharton 2023 NEJM · placebo-subtracted weight loss ~14.7% at 45 mg/day in 36-week Phase 2.
Frias 2023 NEJM · HbA1c reduction up to ~2.1%.
MECHANISM Q+A
▶ What is orforglipron?
Orforglipron (LY3502970) is an orally bioavailable non-peptide small-molecule allosteric agonist of the GLP-1 receptor developed by Eli Lilly. It is the first oral GLP-1 candidate that does not require the specialized absorption formulation used by oral GLP-3.
▶ How does it work?
Orforglipron is a positive allosteric modulator of the GLP-1 receptor. It binds outside the orthosteric peptide-binding pocket and stabilizes the active receptor conformation, producing functional agonist activity.
CITED LITERATURE
- Wharton S, et al.. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 2023. PMID 37364188. link
- Frias JP, et al.. Efficacy and safety of an orally administered GLP-1 receptor agonist (orforglipron) in adults with type 2 diabetes. N Engl J Med 2023. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19